相关实验视频

Updated: Jun 14, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

通过免疫检查点阻塞阻断LAG-3抑制集群与TCR微集群的分离

Akiko Hashimoto-Tane¹, Edward P Bowman², Machie Sakuma¹

¹Laboratory of Cell Signaling, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Frontiers in immunology

|September 5, 2024

概括

淋巴细胞激活基因3 (Lag-3) 通过与T细胞受体微集群共同定位来抑制T细胞激活. 阻断Lag-3会破坏这种相互作用,增强抗癌免疫反应.

科学领域:

免疫学免疫学免疫学
癌症生物学癌症生物学
分子细胞生物学分子细胞生物学

背景情况:

淋巴细胞激活基因3 (Lag-3) 是一种抑制性共受体,在癌症免疫治疗中至关重要.
了解Lag-3在免疫突触中的抑制机制是开发有效治疗的关键.

研究的目的:

为了研究在T细胞激活过程中Lag-3的动态行为.
阐明底层的分子机制 Lag-3介导的T细胞抑制.

主要方法:

在T细胞激活时在免疫突触上对Lag-3局部化和聚类的分析.
使用Lag-3阻断抗体 (Abs) 来评估功能影响.
研究MHC-II独立刺激通路的研究.
采用两种特定的Lag-3/PD-1抗剂.

主要成果:

在T细胞激活时,Lag-3形成集群并与T细胞受体微集群 (TCR-MC) 共定位,类似于PD-1.
阻断Lag-3的Abs可以抑制Lag-3/TCR-MC的同定位,但不能抑制Lag-3集群的形成.
拉格-3抑制是MHC-II独立的;通过破坏拉格-3/TCR-MC联合组装来抑制ABS阻塞.
双特异的Lag-3/PD-1抗剂有效地抑制了两个受体与TCR-MC的集群形成和同定位.

结论:

拉格-3通过与TCR-MC相互作用来抑制T细胞激活.
拉格-3免疫检查点抑制剂 (ICI) 的治疗标是与TCR-MC的拉格-3同局分离.
联合PD-1和Lag-3阻断协同增强T细胞反应.

关键词:

现场行动组-3 在PD-1中使用PD-1.在T细胞激活过程中,在TCR微集群中,微集群是TCR.免疫检查点封锁封锁这是一种抑制性共受体.

更多相关视频

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.